Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
02/2012
02/08/2012CN101060854B 具有抗糖尿病作用的蛋白质水解物 Protein hydrolysates have anti-diabetic action
02/07/2012US8110682 Preparation and use of compounds as aspartyl protease inhibitors
02/07/2012US8110598 Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
02/07/2012US8110566 Therapeutic agents 713
02/07/2012US8110564 Bile acid or bile salt fatty acid conjugates
02/07/2012US8110399 Isolating nestin-positive stem cells, expanding and translplanting into a patient to replace lost or damaged insulin secreting cells; differentiating pancreatic stem cells to obtain cells that produce insulin and other hormones
02/07/2012US8110378 Nucleic acids encoding DCRS5
02/07/2012US8110367 Methods for diagnosing renal disorders
02/07/2012US8110177 Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
02/07/2012CA2520128C Process for the preparation of n-substituted 2-cyanopyrrolidines
02/07/2012CA2492404C Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
02/07/2012CA2488535C Glucocorticoid receptor ligands for the treatment of metabolic disorders
02/07/2012CA2486144C Compositions comprising an angiotensin receptor blocker, a calcium channel blocker and a diuretic
02/07/2012CA2470235C Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
02/03/2012CA2747904A1 Compositions and methods for promoting weight loss and increasing energy
02/02/2012WO2012016229A2 Oxytocin treatment to improve memory and modify blood glucose
02/02/2012WO2012016217A1 Ampk-activating heterocyclic compounds and methods for using the same
02/02/2012WO2012016148A1 Treatment of metabolic syndrome and insulin resistance with citrus flavanones
02/02/2012WO2012015903A1 Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients
02/02/2012WO2012015674A1 THERAPEUTIC USES OF AN FGFR1c ANTIBODY
02/02/2012WO2012015168A2 Pharmaceutical composition comprising rosuvastatin or a pharmaceutically acceptable salt thereof
02/02/2012WO2012015157A1 Novel crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same
02/02/2012WO2012014994A1 Naphthalene derivative
02/02/2012WO2012014993A1 Agent for increasing translation initiation factor or translation elongation factor, and use thereof for medical purposes
02/02/2012WO2012014971A1 Lactic bacterium having an effect of ameliorating metabolic syndrome
02/02/2012WO2012014746A1 Α-lipoic acid complex
02/02/2012WO2012014524A1 Sugar metabolism improving composition, and pharmaceutical preparation containing said composition
02/02/2012WO2012014218A1 Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
02/02/2012WO2012013975A1 Nutritional compositions
02/02/2012WO2012012843A1 Modulators of protease activated receptors
02/02/2012WO2011155689A3 Method for preparing an intermediate of pitavastatin or of the salt thereof
02/02/2012WO2011151436A3 Azepin-derivatives as derivatives as g- protein coupled receptor (gpr43) agonists
02/02/2012WO2011144725A3 Novel methods for preventing or treating diabetes
02/02/2012US20120030779 Compositions and methods for detecting, treating, or preventing reductive stress
02/02/2012US20120029091 Method of controlling the release of an active ingredient from a dosage form
02/02/2012US20120029080 Reduction of risk of obesity
02/02/2012US20120029079 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
02/02/2012US20120029065 Compositions for treating or preventing obesity and insulin resistance disorders
02/02/2012US20120029052 Short Interfering Ribonucleic Acid (siRNA) for Oral Administration
02/02/2012US20120029041 2-aryl imidazoline derivatives
02/02/2012US20120029030 Method for customized dispensing of variable dose drug combination products for individualizing of therapies
02/02/2012US20120029029 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
02/02/2012US20120029028 Compositions and methods for treating hyperlipidemias
02/02/2012US20120029026 Pyridine derivative
02/02/2012US20120029007 Morphinan compounds
02/02/2012US20120029001 Method of treatment of nephrogenic diabetes insipidus
02/02/2012US20120029000 Process for the preparation of alogliptin
02/02/2012US20120028996 Novel oxime derivatives
02/02/2012US20120028995 Novel compounds for medical use as peptidase effectors
02/02/2012US20120028990 3 aryl or heteroaryl-substituted indole derivative
02/02/2012US20120028986 2-heteroaryl-pyrrolo [3,4-c]pyrrole derivatives, and use thereof as scd inhibitors
02/02/2012US20120028983 Novel compound having 3-heteroarylpyrimidin-4-(3h)-one structure and pharmaceutical preparation containing same
02/02/2012US20120028975 Substituted triazolopyridines and analogs thereof
02/02/2012US20120028970 Heteroarylthiomethyl pyridine derivative
02/02/2012US20120028969 Bicyclic acetyl-coa carboxylase inhibitors and uses thereof
02/02/2012US20120028966 Protein kinase inhibitors
02/02/2012US20120028965 Compounds useful as protein kinase inhibitors
02/02/2012US20120028964 Pharmaceutical combination
02/02/2012US20120028962 Fused heterocyclic ring compound
02/02/2012US20120028961 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
02/02/2012US20120028956 Bicyclic mglur5 positive allosteric modulators and methods of making and using same
02/02/2012US20120028955 Bicyclic mglur5 positive allosteric modulators and methods of making and using same
02/02/2012US20120028954 Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same
02/02/2012US20120028940 Functionally selective azanitrile alpha-2c adrenoreceptor agonists
02/02/2012US20120028939 Substituted naphthyridines and their use as medicaments
02/02/2012US20120028926 Phosphate Management with Small Molecules
02/02/2012US20120028922 Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
02/02/2012US20120028897 Methods and compositions for the treatment of fluid retention disorders
02/02/2012US20120028896 Use of fibroblast growth factor fragments
02/02/2012US20120028895 Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control
02/02/2012US20120028894 Peptides, pharmaceutical compositions comprising same and uses thereof
02/02/2012US20120028893 Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses
02/02/2012US20120028892 Inhibitors of fructose 1,6-bisphosphatase and methods of use thereof
02/02/2012US20120028890 Acid containing lipid formulations
02/02/2012US20120028888 Apj receptor compounds
02/02/2012US20120028881 Methods and reagents for diagnosing atheroma
02/02/2012US20120028880 Vegfr-1/nrp-1 targeting peptides
02/02/2012US20120027879 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
02/02/2012US20120027857 Controlled release pharmaceutical compositions comprising o-desmethyl-venlafaxine
02/02/2012US20120027854 Pharmaceutical composition comprising ezetimibe and simvastatin
02/02/2012US20120027845 Adenovirus AD36 E4 ORF1 Protein For Prevention and Treatment of Non-Alcoholic Fatty Liver Disease
02/02/2012US20120027816 Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
02/02/2012US20120027806 Dose selection of adjuvanted synthetic nanocarriers
02/02/2012US20120027781 Neuroprotective and neurorestorative method and compositions
02/02/2012US20120027777 Ljungan virus with improved replication characteristics
02/02/2012US20120027776 Diabetic model
02/02/2012US20120027765 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
02/02/2012US20120027745 Alanine-glyoxylate aminotransferase therapeutics
02/02/2012US20120027738 Maternal supplement
02/02/2012US20120027737 Use of probiotics to ameliorate diet-induced insulin resistance
02/02/2012US20120027736 Anti-obesity agent and anti-obesity food
02/02/2012US20120027729 Methods for treating diabetes
02/02/2012US20120027724 Methods of treating impaired glucose metabolism via administration of algal biomass
02/02/2012US20120027720 Peptide conjugates
02/02/2012US20120027683 Diabetes t cell receptors
02/02/2012US20120027680 Oxime conjugates and methods for their formation and use
02/02/2012US20120024743 Transdermal pharmaceutical preparations
02/02/2012CA2807006A1 Treatment of metabolic syndrome and insulin resistance with citrus flavanones
02/02/2012CA2806749A1 Glp-1 receptor agonist compounds having stabilized regions
02/02/2012CA2806399A1 Recombinantly expressed insulin polypeptides and uses thereof
1 ... 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 ... 1298